Ophthalmology
Dry Eye
3
Pipeline Programs↗
7
Active Trials↗
10
Companies Involved↗
Dry Eye is an early-stage landscape with 3 programs across 10 companies. The most active players are Merck & Co., AbbVie, Takeda. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Analysis
Trial Status
53
clinical trials
Completed37 · 70%
Unknown status8 · 15%
Not yet recruiting4 · 8%
Recruiting3 · 6%
Withdrawn1 · 2%
Clinical Trials
Trial Activity
53 trials
Kera Sol Post-LASIK: A Benefit Study
Recruiting·—·Approved·NCT07155070·60 enrolled
Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks
Not yet recruiting·—·Phase 4·NCT07368595·60 enrolled
Ganyan-1 in Dry Eye
Not yet recruiting·—·N/A·NCT06818487·219 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)